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The nervous system is the most complex organ in the human body, and it is the 
most essential. However nerve cells are particularly precious as, only like muscle 
cells, once formed, they do not replicate. This means that neural injuries cannot 
easily be replaced or repaired. Vitamin D seems to play a pivotal role in protect-
ing these vulnerable and most important structures, but exactly how and to what 
extend is still subject to debate. Systematically reviewing the vast body of research 
on the influence of Vitamin D in various neuropathological processes, we found 
that Vitamin D particularly plays a mitigating role in the development of chronic 
neurodegeneration and the measured response to acutely acquired traumatic and 
non-traumatic nerve cells incidents. Adequate serum levels of Vitamin D before 
the initiation of these processes is increasingly viewed as being neuroprotec-
tive. However, comprehensive data on using it as a treatment during the ongoing 
process or after the injury to neurons is completed are much more ambiguous. A 
recommendation for testing and supplementation of insufficiencies seems to be 
well-founded.
Keywords: Vitamin D, nervous system, neurodegeneration, nerve cell damage, 
traumatic brain injury, acquired brain injury, metabolic encephalopathy, toxic 
encephalopathy, meningitis, stroke, autoimmune processes, neurooncoloy, 
Parkinson’s disease, Alzheimer’s disease
1. Introduction
The nervous system is the most complex organ in the human body. The brain, 
as the nervous system’s command center, is fundamental to the human experience 
as it produces our every thought, action, memory, and feeling. In short, it is our 
apparatus to take in and react to phenomena of the inner and outside world. For this 
task, the brain has a highly interconnected network of approximately one hundred 
billion neurons at its disposal.
These cells, however, are particularly vulnerable. Compared to other cells, 
neurons have markedly higher energy demands. Also, as they neither have a backup 
energy source nor adequate energy stores, they depend on a continuous supply of 
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glucose and oxygen by the blood. Any misalignment between demand and supply 
potentially contributes to permanent damage or cell death. Damage to brain cells 
can occur through events even before birth, as in congenital disorders caused by 
genetic abnormalities or perinatal exposure to noxious conditions. Causative condi-
tions after birth can be divided into acquired, traumatic or non-traumatic, and 
neurodegenerative. Traumatic injuries commonly arise from exposure to external 
mechanical forces, as in traffic accidents, falls, and assaults [1]. Non-traumatic 
injuries derive from either an internal or external source and can be classified 
according to etiology into neurovascular, neoplastic, metabolic, neurotoxic, 
infectious, or autoimmune inflammatory (Figure 1). Only a few epidemiological 
studies provide proportional figures regarding traumatic and non-traumatic brain 
injuries. In one population-based survey on annual incidences of acquired brain 
injuries in Massachusetts [2], the outpatient diagnosis was most frequently related 
to traumatic causes (97%). Of the 3% of non-traumatic etiologies 39% were infec-
tions, in 25% metabolic or toxic conditions, 22% neoplastic, and 14% vascular 
brain diseases. The most severe cases were admitted to ICU, for which the authors 
calculated a ratio of 19% traumatic and 81% non-traumatic causes. The latter were 
predominantly of vascular origin (63%), followed by toxic-metabolic (30%) and 
infectious conditions (7%).
Whereas traumatic assaults primarily cause tearing and breaking of cells and 
structural tissue injuries, non-traumatic incidents tend to affect the metabolic 
functioning on a subcellular basis that either acutely or chronically lead to malfunc-
tion and cell destruction.
Neurons are also especially precious as, only like muscle cells, once formed, 
they do not replicate. This means that abnormalities in the development or injuries 
later in life cannot easily be replaced or repaired. Vitamin D (VD) appears to play 
a critical role in safeguarding these delicate and vital structures. VD deficiency 
affects a broad range of adult brain disorders with various etiologies and causative 
pathomechanisms, according to emerging evidence [3, 4], but it is also essential for 
neuronal growth and pruning in neonates and children [5].
This review examines, for each of the primary injury categories (Figure 1), the 
evidence for VD’s role in the resilience to neuronal damage. It mainly focuses on 
Figure 1. 
Classification of brain injuries in adult life.
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the importance of maintaining adequate VD blood levels before the initiation of 
these processes, the use of VD as treatment during the ongoing process, and as a 
remedy after the injury to neurons has been completed. For conciseness, it explicitly 
concentrates on adult diseases and excludes congenital disorders.
2. Role of Vitamin D in specific neurolopathological processes
2.1 Vitamin D and traumatic neuronal injury
Traumatic brain injury (TBI) may have a wide range of mental and physical 
consequences. Depending on the gravity, type, and location of impact, symptoms 
can vary in severity and duration from mild intermittent attention deficits to 
coma, from discrete transient headaches to permanent and complete incapacity 
or death.
Traumatic brain injury (TBI) occurs at an incidence rate of 235–556/10 million 
[6, 7]. Thus, it is one of the most common neurological diseases, and it is also one 
of the leading causes of morbidity and death among civilians and military person-
nel worldwide [1]. The mortality rate in severe TBI cases can be as high as 40%. 
Survivors, on the other hand, have a disability rate of 55–77% [1, 8, 9], resulting in a 
decrease in quality of life and high socioeconomic costs [10].
TBI is generally divided into two stages: primary and secondary injury. These 
two stages overlap to some extent [11]. Primary brain injury occurs at the moment 
of the initial trauma when mechanical forces cause acute and permanent damage 
to the brain parenchyma. The subsequent secondary brain injury usually starts 
quickly but may progress slowly over months or years [11]. It is, to a large extend, 
caused by microparticles released from damaged tissues that trigger hemostatic, 
ischemic, and inflammatory processes. This eventually leads to lasting secondary 
biochemical and cellular alterations. Depolarization, excitotoxicity, disruption 
of calcium homeostasis, free-radical generation, blood–brain barrier disrup-
tion, ischemic injury, edema formation, and intracranial hypertension are some 
of the most frequently cited mechanisms at play [12]. It is widely believed that 
treatments that can mitigate this cascade of events can considerably improve TBI 
outcomes [11, 12].
VD is thought to have a positive effect on this mechanism at various stages, 
and inadequate levels are linked to more insufficient recovery. In a comprehensive 
review, Colon evaluated the current literature regarding the protective properties of 
VD and its clinical relevance after traumatic brain injury, particularly for military 
personnel [13]. The included in vivo and in vitro studies support that VD modulates 
the immune responses to trauma, diminishes oxidative and toxic damage, and 
inhibits activation and progression of neuroinflammation.
Several observational studies suggested VD deficiency is common in patients 
after TBI (34–46·5%) [14, 15] and is associated with psychiatric deterioration 
(cognition, depression) [14] and possibly an unfavorable disease outcome [15]. 
However, the correlation between VD deficiency and worsening of psychiatric 
disorders may be an epiphenomenon since they are known to be related to VD 
deficiency independently of comorbid TBI [4].
There is no human research examining VD given prophylactically before TBI. 
Animal data suggests, however, that this strategy might be protective. Itho et al. 
observed that seven days of oral supplementation decreased the chances of neu-
ronal damage after TBI in rodents [16]. Another animal study, performed by Wei 
et al., shows similar results, which are thought to be due to reducing the free radical 
damage and preventing apoptosis in damaged neurons [17].
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For post-injury interventions, there are also experimental data. They suggest 
that VD treatment decreases brain edema, attenuates free radical damage, reduces 
neuronal loss in TBI animal models, reduces the inflammatory cytokines TNF-
α, IL-6, and nitric oxide (NO), and attenuates neurological abnormalities after 
ischemia [18–20].
There are also a few human TBI trials. Lee et al. investigated in an open study 
the acute and long-term effects of VD supplementation on the recovery of patients 
with TBI [21]. When administering 100,000 IU cholecalciferol intramuscularly to 
244 patients with deficiency (VD < 30 ng/mL) they found that 3 months outcomes 
assessing performance function (Extended Glasgow Outcome Scale: p = 0.002) 
and cognitive function (Mini Mental Status Examination; p = 0.042, and Clinical 
Dementia Rating; p = 0.044) were better than those of 64 non-deficient control 
patients. The initial low VD status measured when patients arrived at the hospital, 
however, was not found to be a risk factor for mortality. In a randomized placebo-
controlled investigation by Sharma et al., 20 patients with moderate to severe TBI 
received 120,000 IU of VD orally [22]. They had a better overall clinical result 
than 15 placebo-treated patients, but no improvement in mortality rates (14.3% 
vs. 14.3%; p = 0.79). The better outcome was depicted by an increase in the level of 
consciousness from day 2 to day 7 (GCS scores: −3.86 vs. +0.19 points; p 0.0001), a 
shorter mechanical ventilation time (4.7 vs. 8.2 days, p = 0.0001), and a shorter ICU 
stay (6.19 vs. 9.07 days, p = 0.003). In addition, relative to the control group, there 
was a small rise in anti-inflammatory IFN- levels (p = 0.65) and a significant reduc-
tion in cytokines, which are key pro-inflammatory biomarkers for brain damage 
(IL-6: p = 0.08, TNF-: p = 0.02, IL-2: p = 0.36).
Despite promising experimental results, we are unaware of any clinical studies 
on primary (pre-trauma) or secondary (post-trauma) prophylaxis.
2.2 Vitamin D and neurovascular incidents
Stroke is the leading cause of disability and the second most common cause 
of death in the world, causing more than 10% or 5.7 million deaths per year [23]. 
Although relative stroke mortality has declined in the last decades, stroke preva-
lence is increasing due to the demographic shift towards a higher life expectancy 
[23, 24].
Brain tissue injury following stroke results from a complex series of pathophysi-
ological events, including excitotoxicity, oxidative and nitrative stress, inflamma-
tion, and apoptosis [25]. VD is thought to have a beneficial impact on several of 
these factors. In a recently published comprehensive review Yarlagadda et al., based 
on experimental data, suggest several neuroprotective mechanisms of VD concern-
ing vascular health: First, it can increase the expression of insulin-like growth 
factor 1 (IGF-1). IGF-1 can mitigate axon and dendrite degeneration, and by 
activating plasminogen, it also has antithrombotic effects [26]. Second, VD affects 
the vascular system by inducing vasodilation through nitric oxide synthase poten-
tiation (NOS). As a result, it has the ability to decrease blood pressure, increase 
blood supply to neurons after an ischemic stroke, and relieve cerebral vasospasm 
after a subarachnoid hemorrhage. Third, VD stimulates the synthesis of stromal 
cell-derived factor 1α (SDF1α), vascular endothelial growth factor (VEGF), and 
endothelial NOS, thereby displaying an anti-inflammatory effect on myeloid and 
endothelial cells. Finally, VD protects cerebral endothelial cells from post-stroke 
blood–brain barrier (BBB) dysfunction. Relevant factors for this are its antioxidant 
properties, which include inhibiting the development of reactive oxygen species 
(ROS) production, and its ability to prevent tight junction proteins (occludin and 
claudin-5) expression from decreasing.
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It is widely accepted that low plasma concentrations of VD are associated with 
an increased risk of symptomatic ischemic stroke in the general population. In 
a large population-based prospective study, Brøndum-Jacobsen et al. observed 
in 10,170 individuals from the general population a stepwise increasing risk of 
symptomatic ischemic stroke with decreasing plasma VD concentrations [27]. This 
finding was substantiated in a meta-analysis on prospective general population 
studies, including ten studies, 58,384 participants, and 2,644 events [27]. The odds 
ratio of ischemic stroke was 1.54 (1.43–1.65) when comparing the lowest versus 
highest quartile of VD concentrations [27].
Low serum VD levels are also thought to be significantly associated with poor 
prognosis in stroke patients. This has been confirmed by a recent meta-analysis 
by Liu et al. including ten studies and 6845 stroke patients indicating an increased 
risk of poor functional outcome (RR = 1.86; 95% CI = 1.16–2.98), all-cause mortal-
ity (RR = 3.56; 95% CI = 1.54–8.25), and recurrence of stroke (RR 5.49; 95% CI 
2.69–11.23) [28].
While there is a significant body of randomized controlled trials examining 
vascular changes from VD treatment, there are only two on stroke outcome. In 
a non-blinded randomized controlled trial on 66 VD-deficient and -insufficient 
stroke patients, Narasimhan et al. tested the effects of administering single doses 
of Cholecalciferol (600,000 IU i.m.). The three months improvements of func-
tional outcomes were significantly more prominent in the treatment group than 
in the control group (Scandinavian Stroke Scale: 6.39 ± 4.56 vs. 2.5 ± 2.20 points, 
p < 0.001) [29]. The randomized controlled trial by Gupta et al. tested VD-calcium 
supplementation in 25 out of 53 VD-deficient stroke patients (<75 nmol/L). After six 
months, patients in the treatment arm had a decreased mortality risk (HR = 0.26) 
and attained a better functional outcome (modified Rankin Scale score) (OR = 1.90) 
compared to those of the untreated group [30].
There are two recent studies to clarify the effects of oral VD supplementation on 
the outcomes in post-acute stroke patients in a rehabilitation setting. One random-
ized, double-blind placebo-controlled study by Sari et al. assessed if VD treatment 
(300,000 IU i.m.) affects the outcomes of rehabilitation and balance in 72 VD defi-
cient hemiplegic stroke patients. By the end of the third month, activity levels (modi-
fied Barthel index scores) had significantly increased, and balance recovery (Berg 
balance scale) had accelerated in the supplementation group compared to the group 
of untreated patients [31]. Momosaki et al. conducted a multicenter, randomized, 
double-blind, placebo-controlled, parallel-group trial in 100 patients admitted to a 
convalescent rehabilitation ward after having an acute stroke [32]. After eight weeks 
of oral VD supplementation (2,000 IU/day), there were no between-group differ-
ences in Barthel Index scores, in Barthel Index efficiency, handgrip strength, and calf 
circumference. Thus, based on their findings and in contrast to those of the previous 
study, they cannot report on a positive effect of VD on rehabilitation outcomes.
2.3 Vitamin D and neurooncologic processes
Glioblastoma multiforme (GBM) is the most commonly occurring malignant 
primary brain tumor, representing 77–81% of all primary CNS malignancies 
[33]. The annual incidence rate is 0.59 to 5 per 100,000 persons. GBM is a grade 
IV diffuse astrocytic and oligodendroglial tumor with a poor prognosis. Despite 
recently improved standard of care treatment involving surgery, chemo, and 
radiation therapy, median survival is 14.6 months. Reasons for GBM development 
are presumably multifactorial, but exact pathomechanisms are not well understood. 
The inactivation of apoptotic pathways seems to play an essential role in facilitating 
tumorigenesis and –progression [34].
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One of the risk factors to develop GBM is birth in the winter months, suggesting 
a VD association that goes back decades before disease onset [35]. Also, expression 
of Vitamin D Receptor (VDR) is associated with a good prognosis in GBM [36]. 
Zigmont et al. reported an inverse association between VD consumption and GBM 
risk among men aged 56 years and older. Levels of VD in men >56 were inversely 
related to the occurrence of high-grade glioma (p = 0.04), i.e., older men with high 
levels (>66 nmol/L) showing a reduced propensity. This association even existed 
in samples drawn premorbid i.e. from ≥2 yr. (OR = 0.59; 95% CI = 0.38, 0.91) 
to ≥15 yr. before diagnosis (OR = 0.61; 95% CI = 0.38,0.96) [37]. This temporal 
sequence is another piece of evidence for a causative relation.
Mulpur et al. explain possible mechanisms of VD as treatment option: [38]. 
First, There is direct cancer control by influencing the signaling of macrophages 
and dendritic cells of the immune system and activating the tumor suppressor p53. 
It is well known, for example, that in other malignancies like breast cancer, VD 
down-regulates Akt and MDM2 leading to TGFβ-1-dependent growth inhibition 
[34]. In GBM, VD can inhibit the hedgehog signaling pathway and disable brain 
tumor stem cells (BTSCs). Due to their importance in tumor formation, recur-
rence, and metastasis, BTSCs are considered to be the tumor’s driving force. Then, 
adequate VD availability also has secondary benefits. The immune system’s role is 
bolstered, which indirectly inhibits tumor cell growth. By reducing some of the 
unintended side effects of standard therapy, sufficient doses can be given, and 
treatment adherence can be improved [38].
There is but one published prospective open label study in humans that investi-
gated in 470 newly diagnosed GBM-patients VD self-use, among other alternative 
medications. The sixty patients taking VD as an individual supplement had reduced 
mortality when compared with non-users (age-adjusted HR = 0.68; p = 0.02) [38].
VD has not yet been studied in a controlled clinical trial as a prophylactic or 
treatment in late-stage GBM or other primary brain tumors, as far as I am aware.
2.4 Vitamin D and infections
Meningitis and encephalitis, the infectious diseases of the brain tissue and the 
covering membranes, are endowed with substantial rates of mortality and with 
long-term sequelae in survivors. The WHO estimates the global incident cases to be 
2.82 million and the death rate to be 318,400. Globally in 2016, 1.48 million YLDs 
and 21.87 million DALYs were due to meningitis [39]. Incidence, mortality and dis-
ability rates vary significantly according to region and pathogen. Bacterial infection 
is a major cause of meningitis, globally outnumbering other classes of organisms 
such as viruses, fungi, or parasites [39].
The mechanism of infection-induced brain cell damage is elaborately explained 
by Chaudhry, Hoffman and Weber [40]: They state that the cascade starts with 
pathogen invasion, which triggers activation of the immune system, including 
white blood cells, complement, and immunoglobulins. Immune cells and the dam-
aged endothelial cells start to release cytokines, matrix metalloproteinases (MMPs), 
and nitric oxide (NO). While cytokines induce capillary wall changes in the blood–
brain barrier, the MMPs, and NO, on the other hand, stimulate vasodilation that 
alters the cerebral blood flow. Cytokine release provokes the expression of more 
leukocyte receptors, which increases both white blood cell binding, i.e., adherence 
to capillary endothelium as well as extravasation. This then leads to further damage 
to the meninges and endothelial cells, thereby stimulating cytotoxic reactive oxygen 
species production and release of even more cytokines and chemokines. This 
coordinated assault aims to eliminate the invading pathogen, but it also harms and 
destroys nearby brain cells. Increased cytotoxic metabolite levels and permeability 
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may further lead to cerebral edema and elevated intracerebral pressure. Those two 
factors, together with the altered blood flow, causes reduced perfusion pressure and 
possibly neural ischemia.
As Guevara et al. and Golpour et al. pointed out in their overviews, [41, 42]. 
VD exerts a wide range of effects on the very pathomechanisms implicated in brain 
infection. The targets of these actions can be both host cells by enhancing innate 
immunomodulatory activity as well as pathogen cells by displaying direct antibacte-
rial and antimicrobial properties [41, 42]. The authors elucidate that VD, which 
is signaling through the VDR, stimulates innate immune cell functions, including 
phagocytosis, production of antimicrobial peptides (AMPs), and reactive oxygen 
species (ROS). It is also responsible for upregulation of the pattern recognition 
receptors (PRR) TLR2 and NOD2 and generation of TIMP-1, which downregulates 
matrix metalloproteinases (MMPs) [41]. Furthermore, VD inhibits the production 
of MMPs and proinflammatory cytokines. VD also deranges Th17 programming, 
which instead leads to the promotion of the regulatory T cell phenotype [41]. But, 
VD also directly impedes the growth, viability, and biofilm formation of various 
bacteria [41–43].
Infections with Streptococci and Mycobacteria, both not infrequently causing 
meningitis, have been shown to be repressed in the presence of adequate VD levels. 
In an in vitro experiment on isolated human neutrophils, Subramanian et al. found 
that VD boosts neutrophil killing of S. pneumoniae while also lowering inflamma-
tory responses and apoptosis [44]. Rode et al. found in their experiments with naive 
human CD4+ T cells that in the defense against M. tuberculosis, there is an increased 
expression of VDR and an upregulation of VD-1 hydroxylase genes. VD blocks M. 
tuberculosis-induced cathelicidin downregulation and enables Th1 differentiation 
and IFN secretion, both of which are protective. These processes promoted M. 
tuberculosis intracellular death in human macrophages and monocytes [45].
While there is plenty of studies on lung, gut, or generalized infections in the 
form of sepsis [46], there is hardly any data on infections of the CNS. Regarding 
the effect of VD deficiency and meningitis outcome in adults, there is but one study 
on tuberculous meningitis (TBM). Dangeti et al. examined prospectively 40 HIV 
patients with tuberculous meningitis and found that there was but a trend for  
lower VD levels in patients with a poor compared to those with a good outcome 
(28.30 +/− 14.96 vs. 35.92 +/− 17.11 ng/ml, p = 0.141) [47].
Contrary to somewhat positive results of a meta-analysis including eight add-on 
supplementation studies to treat pulmonary tuberculosis, [46] there are no data on 
supplementing tuberculous meningitis patients. Neither are there any trials in the 
adult population on encephalitis or meningitis caused by other pathogens. There is 
also no study investigating prophylactic effects in highly exposed individuals.
2.5 Vitamin D and neuro-autoimmune processes
Multiple sclerosis (MS) is the most common inflammatory autoimmune dis-
order of the central nervous system, afflicting worldwide more than 2.8 million 
people, most of them young and of the female gender [48]. MS is a chronic, incur-
able condition that causes severe incapacity in one-third of patients after either a 
relapsing–remitting or gradual, steadily progressing disease path. It is also the most 
frequent cause of non-traumatic neurological disability among young adults in the 
Western Hemisphere [49].
The pathological hallmark, as the name implies, are multifocal demyelinated 
lesions, or “plaques”, followed by gliosis. Perivascular inflammatory infiltration and 
focal blood–brain barrier breakdown can be seen in these plaques [50]. However, 
there is diffuse tissue damage even in the normal-appearing white and gray matter. 
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Here we find a low-grade diffuse inflammation with perivascular accumulation 
and parenchymal infiltration of lymphocytes, diffuse microglial activation, diffuse 
astrocytic gliosis, and diffuse neural or neuroaxonal loss and injury [50]. Different 
immunological mechanisms seem to be involved in the induction of tissue injury, 
but microglia activation associated with oxidative injury and mitochondrial damage 
appears to play a dominant role [50].
Several observational studies have shown that low serum VD levels are associ-
ated with an increased risk of developing MS, as well as increased disease activity 
and progression [51]. Miclea summarizes the various factors on how VD can 
positively influence MS pathology on a molecular level [51]: The ability of VD to 
suppress the progression of the experimental disease is attributed to its modulation 
of T cell trafficking into the CNS, its inhibition of Th1 cells, and its stimulation of 
IL-10 production. Demyelination is reduced via VD’s activation of microglia result-
ing in the clearance of myelin debris and phagocytosis of pathological proteins 
such as amyloid-β peptides. Another supportive aspect is VD’s ability to reduce the 
expression of inducible nitric acid synthase, a pro-inflammatory enzyme. Lastly, 
VD might induce remyelination by stimulating the maturation of oligodendrocytes 
and the activation of astrocytes.
There is no human study to examine the potential of VD to be used as a preven-
tive therapy to control MS severity. Minura conducted a preclinical study in the 
MS animal model (EAE). Mice injected with VD but not those with VD analog had 
better outcomes. VD’s down-modulatory potential was demonstrated in the histo-
pathology of VD-treated animals, which showed reduced recruitment of inflamma-
tory cells, mRNA expression of inflammatory parameters, and CNS demyelination.
Optic neuritis is an acute inflammatory and demyelinating disease of the optic 
nerve, of which at least half of monosymptomatic patients will eventually convert to 
clinically manifest MS. There is one double-blind, randomized, placebo-controlled 
pilot clinical trial examining the preventive effect of VD supplementation on 
conversion to MS [52]. When compared to the 15 patients in the placebo group, the 
fifteen VD deficient patients who received 50,000 IU of VD weekly for 12 months 
had a 68.4% lower risk of conversion to MS (relative risk = 0.316, p = 0.007) and a 
significantly lower incidence rate-ratio of demyelinating plaques in MRI (i.e., less 
cortical, juxtacortical, and corpus callosal plaques, less new T2 lesions, less new gad-
olinium-enhancing lesions, and less T1-weighted black holes) (p = 0.001 – 0.005).
Concerning supplementation of VD for patients with clinical manifest MS, there 
is a large number of studies and several meta-analyses. Overall results, however, 
were inconclusive. A Cochrane review pointed out that the unresolved nature of 
the final conclusion rests in great part in the low quality of included studies, but 
particularly in the heterogeneity of patient cohorts and the small sample size of 
most studies [53]. Taking this into consideration, Martínez-Lapiscina et al., in a 
most recent meta-analysis with 13 high-quality studies and 3,498 patients with early 
relapsing MS, showed that each 25 nmol/L increase in serum VD levels brings with 
it an average 10% decrease in new relapses and a 14–31% reduction in the risk of 
new radiological inflammatory activity [54].
The three most recent randomized controlled VD add-on trials published since 
2019 that were not included in the previous meta-analyses showed mixed results. 
The SOLAR trial studied the effect of high-dose VD supplementation (14,007 IU/d) 
vs. placebo as an add-on therapy to interferon beta-1a. It demonstrated that at week 
48 the 113 high-dose VD (14,007 IU/d) treated compared to 116 untreated patients 
had better MRI outcomes for combined unique active lesions (incidence rate ratio 
0.68; 95% CI = 0.52–0.89; p = 0.0045) and for change from baseline in total volume 
of T2 lesions (difference in mean ranks: −0.074; p = 0.035). However, there was 
no difference regarding the development of the proportion of patients with no 
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evidence of disease activity [55]. The CHOLINE trial reported in the VD group 
after 96 weeks a slower progression of disability (EDSS) (p = 0.026), better MRI 
outcomes with fewer new hypointense T1-weighted lesions (p = 0.025), and a lower 
volume of hypointense T1-weighted lesions (p = 0.031). However, there was only a 
marginal downward trend in the annualized relapse rate [56]. In the EVIDIMS trial, 
at the 18 months followups, there was no difference between high- (20,400 IU) 
and low-dose (400 IU) treatment arms regarding clinical outcomes (relapse rates, 
disability progression) and radiographical markers (T2-weighted lesion, contrast-
enhancing lesion, brain atrophy) [57]. Unfortunately, only data on intergroup dif-
ferences, not on intragroup shifts from baseline, were provided in this publication.
2.6 Vitamin D and toxic or metabolic encephalopathy
The National Institute of Neurological Disorders and Stroke (NINDS) defines 
encephalopathy as any diffuse disease of the brain that alters brain function or 
structure … [in a way that it leads to an] altered mental status [58]. Patients can 
exhibit acute confusion, attention deficits, seizures, and coma, or more insidious 
chronic symptoms, such as mood disturbances and fatigue.
Even though toxic encephalopathy is a condition that can be coded in ICD 10, 
there is no sound data on its epidemiology, neither regionally nor internationally.
Encephalopathies can, according to etiology, be classified into toxic and meta-
bolic and, according to disease course, into acute and chronic. Toxic causes are 
medications, illicit drugs, or toxic chemicals. Metabolic etiologies include electro-
lyte imbalance, organ failure (e.g., hepatic, renal), hypoxemia, sepsis, dehydra-
tion, hypertension, hereditary enzyme deficiencies, and vitamin deficiency (e.g., 
Wernicke: thiamine). Chronic encephalopathies are usually slowly progressing and 
lead to permanent, mostly irreversible, structural changes. Only rarely, depending 
on early detection and treatment, they may be halted or reversed. In contrast, acute 
encephalopathies often have a good outcome as soon as underlying abnormalities 
are corrected. Whereas many metabolic encephalopathies have an acute onset, toxic 
encephalopathies can have acute (e.g., CO) or chronic (e.g., heavy metals) disease 
courses.
Encephalopathies are morphologically characterized by cytotoxic cerebral 
edema (membrane damage), disruption of the membrane enzyme systems, axonal 
and neuronal injury, focal necrosis, and impairment of neurotransmitters secretion 
or receptor function [59]. Pathogenetic mechanisms include impairment of oxida-
tive metabolism, protein synthesis, cytoskeletal structure, as well as the injury of 
capillaries and astroglial and microglial reactions [59].
There are but a few hints of an association of environmental toxins and VD, one 
of which concerns a patient’s vulnerability to toxins. Studies using genetic markers 
of susceptibility suggest that genes can make specific individuals more vulnerable 
to environmental toxins. One of these candidates is the VDR gene. Recent findings 
suggest that VDR polymorphism influences, for example, the accumulation of lead in 
bones and could thus serve as a marker for lead-induced chronic encephalopathy [60].
Air pollutants and other environmental chemicals may trigger VD deficiency, 
either directly or indirectly. The exact mechanism is still not clear, but for heavy 
metals, it was suggested that it might be by increasing renal tubular dysfunction 
and downregulating the transcription of CYPs [61]. Endocrine-disrupting chemi-
cals, on the other hand, may either directly inhibit the activity and expression of 
CYPs or can do this through indirect pathways [61]. Finally, carbon monoxide (CO) 
interferes with cytochrome-dependent cellular functions, but how it does this is 
not fully understood. It is known, however, that CO is released from CO-releasing 
molecules (CORM) and that CORM-2 decreases VD synthesis [62].
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For metabolic encephalopathy, there is but one study. In this prospective inves-
tigation by Yousif et al. on 135 HCV-related liver cirrhosis patients, he detected 
significantly lower VD levels ((6.81 ± 2.75, vs. 16.28 ± 6.60; p < o.o5) in the 45 
patients that developed hepatic encephalopathy (HE) [63]. HE patients with 
particularly severe deficiency had a significantly higher mortality rate (HR = 2.76, 
p = 0.001).
There are no retrospective or prospective controlled studies that have looked 
into the effect of VD as a treatment for encephalopathies.
2.7 Vitamin D and neurodegeneration
Neurodegeneration is characterized by selective dysfunction and progressive 
loss of synapses and neurons associated with pathologically altered proteins that 
deposit primarily in the human central nervous system [64]. Although each neuro-
degenerative disease is differentiated from the others by distinct protein accumula-
tions and anatomic vulnerability of specific neuronal populations, they all share 
several fundamental mechanisms that are associated with progressive neuronal loss 
and death. These pathomechanisms include inflammation, apoptosis, oxidative 
stress, and proteotoxic stress linked to defects in the ubiquitin–proteasomal and 
autophagosomal/lysosomal systems [65].
In the following paragraphs, we will discuss the role of VD in Alzheimer’s 
disease (AD) and Parkinson’s disease (PD) as typical examples of neurodegenera-
tive disorders.
2.7.1 Alzheimer’s dementia
Dementia is a syndrome in which there is deterioration in memory, thinking, 
behavior and the ability to perform everyday activities. Globally, around 50 million 
people, of which 62% are women and 38% are men, have dementia, and there are 
nearly 10 million new cases every year. It is one of the major causes of disability and 
dependency among older people worldwide. Dementia, accounting for 2·4 million 
deaths is the fifth leading cause of death globally [66].
AD is the most common form of dementia, making up 60–70% of cases, [67] 
and is also the most common neurodegenerative disease. The cardinal pathological 
features of the disease are senile plaques and neurofibrillary tangles. Senile plaques 
consist of a central core of beta-amyloid, a 4-kD peptide. They are found outside of 
neurons and are typically surrounded by neurites that are abnormally configured 
[68]. Senile plaques are thought to contribute to the damage and death of neurons 
by interfering with neuron-to-neuron communication at synapses. Neurofibrillary 
tangles are made up of abnormally phosphorylated tau that accumulates in the peri-
karyal cytoplasm of specific neurons [68]. They block the intracellular transport of 
nutrients and other essential molecules [69]. Both senile plaques and neurofibrillary 
tangles activate microglia, with the aim of clearing toxic proteins and debris from 
dead and dying cells [69]. Chronic inflammation may set in when the microglia 
cannot keep up with all that needs to be cleared [69]. Brain function is further 
compromised by decreases in the brain’s ability to metabolize glucose, its primary 
source of energy [69].
Based on experimental findings of treatment with the VD analog, Maxacalcitol, 
Saad El-Din suggested that VD may improve the histopathological picture of the 
brains of AD rats [70]. Also, it might significantly increase expression of Nrf2 
and its downstream effectors (HO-1 and GSH), improve serum levels of calcium, 
decrease neuro-inflammation and Amyloid β load, as well as hyperphosphorylation 
of MAPK-38, ERK1/2, and tau proteins [70]. Masoumi was able to stimulate AD 
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patients’ macrophages with VD so that Aß phagocytosis and clearance increased 
while at the same time apoptosis decreased [71].
Cohort studies, including several meta-analyses, essentially indicate that VD defi-
ciency is associated with a significantly increased risk of AD and all-cause dementia. 
There are three important prospective studies on the effect of VD to mitigate the risk 
of developing AD. Littlejohns et al. studied 1,658 older people (mean age 73.6 years), 
of which 102 developed AD after being observed for 5.6 years. VD deficiency, accord-
ing to his results, is related to a substantially higher risk of AD. When compared to 
participants with adequate serum levels, the risk of developing AD was higher in 
severely (VD 25 nmol/L; HR = 2.22; 95 % CI = 1.02–4.83) and to a lesser extent also in 
moderately deficient (VD 50 nmol/L; HR = 1.69; 95 % CI = 1.06–2.69) patients [72]. 
Annweiler et al. investigating the effect of dietary VD intake in 498 older women fol-
lowed for seven years, also confirmed that higher intake of VD (on average 2336.41 IU 
weekly) reduced AD risk (OR = 0.23; 95% CI = 0.08–0.67) compared to those with 
lower intake [73]. SanMartin et al. conducted a study to see whether VD might have 
properties that could prevent subjects with mild cognitive impairment (MCI) from 
deteriorating and thus converting to AD. After six months of VD supplementation, 
they found that correcting low VD levels would protect lymphocytes from oxidative 
death and increase Aβ1–40 plasma levels in 16 MCI patients. Aβ1–40 was monitored 
because it served as a marker for Aβ-amyloid clearance from the brain. Additionally, 
at the 18-month follow-up, cognitive status was assessed, and scores on the Clinical 
Dementia Rating (CDR), Montreal Cognitive Assessment (MoCA), and Memory 
Index Score improved [74].
Two trials looked at the effect of VD in patients with established AD. In a 
retrospective study by Chaves et al. on 202 patients with mild stage AD, the time 
of progression to severe stage of AD was shorter under VD compared with those 
without this treatment (5.4 ± 0.4 years vs. 4.4 ± 0.16 years, p = 0.003) [75]. The 
randomized, double-blind, placebo-controlled trial by Jingya Jia et al. on 210 AD 
patients suggests that daily oral VD supplementation (800 IU/day) over 12 months 
may improve cognitive function reflected by information retrieval, arithmetic, 
digit span, vocabulary, block design, and picture arrange scores (p < 0.05). It also 
had positive effects on the Aβ-related biomarkers in plasma Aβ42, APP, BACE1, 
APPmRNA, BACE1mRNA (p < 0.001) [76].
2.7.2 Parkinson’s disease and other movement disorders
Parkinson’s disease (PD) is a slowly progressing disabling disease characterized 
by bradykinesia, tremor, rigidity, and eventually postural instability. Furthermore, 
non-motor symptoms such as autonomic, sensory, or psychiatric symptoms also 
occur in most patients. PD is the second most common neurodegenerative dis-
order worldwide, with a prevalence of 1% in populations over 60 years of age in 
developed countries [77]. Males outnumber women one and a half to one [77]. In 
2016 PD was affecting more than 6.1 million people globally and caused 3.2 million 
DALYs and 211,296 deaths [78].
PD is characterized by the loss of dopaminergic neurons in the substantia nigra 
pars compacta, but it also affects a variety of other brain regions. Lewy bodies are 
the histopathological hallmark of PD and are also held accountable for initiating 
and maintaining the pathological process [79]. They include several misfolded 
amyloid proteins such as alpha-synuclein (SNCA), phosphorylated tau (p-tau), 
and amyloid beta-protein (Aß). Although the exact mechanism of how misfolded 
proteins accumulate and cause neurodegeneration is unknown, mitochondrial 
damage, energy failure, oxidative stress, excitotoxicity, impaired protein clearance, 
and cell-autonomous mechanisms are all thought to play a role [79]. According 
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to Braak’s widely accepted theory, these processes are triggered by a “prion-like 
protein infection”, starting in the gut or nasal mucosa and is then propagated via 
olfactory pulp or the vagal nerve to the brainstem. It then spreads to successive parts 
of the brain in a chronologically predictable rostrocaudal sequence [80].
VD has been linked to PD-pathology through its effects on L-type voltage-
sensitive calcium channels (L-VSCC), nerve growth factor (NGF), matrix metal-
loproteinases (MMPs), prostaglandins (PGs), cyclooxygenase-2 (COX-2), reactive 
oxygen species (ROS), and nitric oxide synthase (NOS) [81]. VD has also been 
shown to play a role in dopamine synthesis by regulating the tyrosine hydroxylase 
gene [81].
Seven observational studies and a meta-analysis [82] have looked into the 
connection between VD and PD and, except for one, have consistently found low 
serum VD levels in PD patients. Like for other basal ganglia disorders [83], the 
prevalence of VD deficiency in PD is high (57% - 71%) [82]. However, data to tie 
this to a causal relationship have been controversial. Using the Finish National 
Drug-Reimbursement Database, Knekt et al. looked at the connection between VD 
levels in midlife and the risk of developing PD later in life. Throughout the 29-year 
follow-up period, 50 of the 3,173 men and women in the sample developed PD. 
Individuals with higher serum VD concentrations had a 65% lower PD risk than 
those with insufficient levels. After adjustment for confounding factors, the relative 
risk highest vs. lowest quartiles was 0.33 (95% CI = 0.14–0.80). Contrary to that, 
Shrestha et al. in their U.S. population-based prospective cohort study including 
15,792 individuals aged 45 to 64 years, discovered no connection between serum 
VD concentrations and PD risk [84]. A total of 67 participants developed PD after 
a median of 17 years of follow-up. For those who developed PD and those who did 
not, the mean serum concentrations of VD were comparable (25.6 ± 8.4 ng/mL vs. 
24.2 ± 8.5 ng/mL, p = 0.24).
Several meta-analyses have looked into the connection between VDR poly-
morphisms and PD risk. The most recent investigation by Wang et al. suggests 
that the SNP FokI is linked to a lower risk of PD in Asian but not in Caucasian 
 populations [85].
There are three prospective PD supplementation studies and one small meta-
analysis, but results are mixed [86]. Suzuki et al. randomized 114 PD patients to 
receive 1,200 IU of VD a day (n = 58) or a placebo (n = 56) for a period of 12 months 
[87]. The intervention group’s serum VD level doubled, while the placebo group’s 
level remained unchanged. At the same time, the intervention group’s motor scores 
(H&Y stage, UPDRS) remained stable, while the placebo group’s scores signifi-
cantly deteriorated (difference between groups: p = 0.005). They concluded that 
VD supplementation might help stabilize PD motor aspects, at least for a short 
period [87]. Habibi et al. randomized 120 PD patients with levodopa-induced dys-
kinesia to receive either 1,000 IU of VD a day or a placebo [88]. At the 3-month fol-
low-up, there was no difference in scores for levodopa-induced dyskinesia (UPDRS 
IV sub score) or motor function (UPDRS III motor score) [88]. Hiller et a. looked 
at balance problems and falls, [89] which are considered to be particularly frequent 
in PD [90], a major cause of morbidity and mortality, and challenging to treat, 
even with non-pharmacological therapies specifically designed to alleviate balance 
deficits [91]. They conducted a pilot (n = 58) randomized, double-blind interven-
tion trial to measure the effects of 16 weeks of high dose VD (10,000 IU/day) on 
PD symptoms, but mainly on balance. Despite an increase in VD serum concen-
trations (30.2 ng/ml to 61.1 ng/ml), in the 27 VD treated patients, the Sensory 
Organization Test did not show a substantial improvement in balance (p = 0.43). A 
post hoc analysis comparing treatment effects in younger (age < 67 yrs.) and older 













Brain injury classification VitD ≈ Risk VitD ≈ outcome experimental prophylaxis treatment early treatment late
Aquired Traumatic D + * D * C + B +
vascular A + * A + * C + C + B +/−
Neoplastic D + D +
Infectious D -
Autoimmune C + * C + * C + C + A +/−
Toxic-Metabolic B +
Degenerative Alzheimer’s D. A ++/− D + C +
Parkinson’s D. B +/− B (+)/−
Study quality: D: observational studies only, C: one randomized controlled trial (RCT) or one representative cohort study (RCS), B: more than one RCT or RCS, A: one or more meta-Analysis.
Study-outcome: Favorable +, very favorable ++, unfavorable - (*same study for two aspects).
Table 1. 
Characteristics of studies on vitamin D and neuropathological processes.
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of 10.6 points in the group of younger PD patients (p = 0.012) [89]. There was, 
however, no effect on other PD symptoms.
In summary, there exist a large number of studies on VD and neurological 
diseases, but there is a broad variety of levels of evidence for individual neu-
ropathological processes, and the result is not always favorable (Table 1). On 
epidemiological trials, the most widespread agreement is that VD deficiency is a 
risk factor for acquired and neurodegenerative nerve cell injury (Vit D ≈ risk) and 
a poor outcome (Vit D ≈ outcome) once the injury has occurred. Epidemiological 
studies with the highest degree of evidence (A) exist for stroke and AD, but there 
are none for brain infections and toxic-metabolic encephalopathy. VD as medica-
tion, particularly when used early in the process, has been extensively investigated 
in all categories with high-quality research for autoimmune diseases of the brain 
(A), neuro-trauma (B), and PD (B). VD was only studied as a late-stage treatment 
for stroke, with high-quality evidence (A) but mixed results, and as a prophylaxis 
for autoimmune diseases and AD, with medium to low-quality evidence (C and D) 
and positive results.
3. Conclusion
Going through the meanwhile numerous studies on the influence of VD in the 
various neuropathological processes, there is strong support that VD particularly 
plays a mitigating role in the development of chronic neurodegeneration and the 
measured response to acutely acquired nerve cell injuries and potential secondary 
damages. The mechanisms of cell afflictions and recovery are complex and not fully 
understood. However, despite the differences depending on the type of insult, there 
appear to be some common pathways in which VD is relevant. Adequate serum 
levels of VD prior to the initiation of these processes are now be thought to be 
neuroprotective. However, comprehensive data on using it as a treatment during the 
ongoing process or after the injury to neurons has been completed are much vaguer. 
(Table 1) There appears to be no evidence to support its use in patients who already 
have adequate levels in their system. Extremely high doses seem not to provide any 
added benefit but may increase the risk of VD intoxication [92].
There are a few other reviews on the link between VD and diseases of the brain. 
This work differs from these as it is currently the most up-to-date survey. But, more 
importantly, while most of them covered either specific subsections, for example, 
neurodegenerative [93] and psychiatric diseases [4], or disease groups like dementias 
[72] and movement disorders [83], this is one of the few articles that addresses the 
full spectrum of neurological conditions. Furthermore, it is the first to focus on 
the neuropathological process. This is significant because it refocuses attention on 
the basic science track, where there are still so many uncharted regions and where 
scientific advances can possibly have therapeutic implications.
Due to a vast body of evidence of recorded benefits, a consistent safety record, 
and low costs, VD deficiency should be assessed and corrected on a routine basis 
in all neurological disorders, regardless of the underlying neuropathological 
mechanism.
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